These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21777819

  • 21. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C, Adams O, Kieseier BC.
    N Engl J Med; 2009 Dec 17; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 17; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 24. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.
    Arch Neurol; 2009 Aug 17; 66(8):1016-20. PubMed ID: 19667224
    [Abstract] [Full Text] [Related]

  • 25. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 26. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 11; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.
    Havla J, Hohlfeld R, Kümpfel T.
    J Neurol; 2014 Jan 11; 261(1):232-4. PubMed ID: 24276521
    [No Abstract] [Full Text] [Related]

  • 29. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Jan 11; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 30. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
    Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G, MS-SIN Study Group.
    Neurol Sci; 2011 Apr 11; 32(2):351-8. PubMed ID: 21234775
    [Abstract] [Full Text] [Related]

  • 31. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 32. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct 17; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

  • 33. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 34. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug 17; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 35. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 17; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.
    Mult Scler; 2013 Aug 17; 19(9):1226-9. PubMed ID: 23508652
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug 17; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.